PCI Biotech: Gael L'Hévéder employed as Head of Business Development

Oslo, 3 April 2013 - PCI Biotech (PCIB) the Norwegian biopharmaceutical company, reported today that Mr. Gael L'Hévéder has joined their team as Head of Business Development. Mr. L'Hévéder has more than 15 years industry experience gained in both large pharmaceutical companies such as Sanofi-Aventis, Baxter and Roche, and in biotech start-ups. Throughout his career he has worked both in US and Europe, and he has held several relevant positions, including Business Development Director, Pharma Partnering at Roche and European Business Intelligence Director at Baxter Healthcare.

-I am very happy to have Gael as our new Head of Business Development. He will bring valuable experience as well as a global network. PCI Biotech is in a crucial period with regard to business development, and with Gael onboard the company is even better positioned to implement our partnering strategy, says CEO Per Walday.

Gael L'Hévéder is a 44 year old dual French/US citizen who received a Masters of Science in organic chemistry from Université Louis Pasteur, Strasbourg, France. He will start in his position 8 April 2013.

About PCI Biotech
PCI Biotech is a Norwegian biopharmaceutical company developing a novel light directed drug delivery system based on its patented photochemical internalisation (PCI) technology. Originating from world leading research at the Norwegian Radium Hospital, the PCI method involves first injecting Amphinex® and thereafter the therapeutic drug to be specifically delivered to the diseased cells. When these are illuminated the cells' endosomes are ruptured to allow successful intracellular delivery of the drug.

PCI can enhance the delivery of all molecules taken into the cell by endocytosis. This includes most types of macromolecules, drugs carried by antibodies or nanoparticles, as well as some small molecule drugs.

PCI Biotech follows a dual strategy of using its technology to improve the effect both of existing drugs and for emerging treatments such as gene therapy. PCI Biotech's first clinical study combines the proven photosensitiser Amphinex® with the cytotoxic agent bleomycin. A clinical study for the use of PCI in treatment of patients with bile duct cancer is being planned. In this indication, Amphinex will be used in combination with the generic cytotoxic agent gemcitabine. The aim is to include the first patient by end of 1H 2013. A preclinical program to investigate the use of PCI to enhance the effect of vaccines is ongoing, with the aim to establish a protocol for a clinical study that can start in 2013.

For more information visit: www.pcibiotech.com

Contact information:
PCI Biotech Holding ASA, Strandveien 55, N-1366 Lysaker
Per Walday, CEO, pw@pcibiotech.no, Mobile: +47 917 93 429
Bernt-Olav Røttingsnes, CFO, bor@pcibiotech.no, Mobile: +47 913 47 021